title: Suppression of the Oncogenic Transcription Factor FOXM1 by Proteasome Inhibitors.
abstract: The oncogenic transcription factor FOXM1 is one of the key regulators of tumorigenesis. We found that FOXM1 upregulates its own transcription and its protein stability depends on its interaction with the chaperone nucleophosmin. We also determined that FOXM1 is negatively regulated by the tumor suppressor p53. We identified the thiazole antibiotics Siomycin A and thiostrepton as inhibitors of transcriptional activity and FOXM1 expression via proteasome inhibition. In addition, we found that all tested proteasome inhibitors target FOXM1. We showed synergy between thiostrepton and bortezomib in different human cancer cell lines and in vivo. We generated isogenic human cancer cell lines of different origin with wild-type p53 or p53 knockdown and we demonstrated that proteasome inhibitors induce p53-independent apoptosis in these cells. Using RNA-interference or proteasome inhibitors to inhibit FOXM1 we found that suppression of FOXM1 sensitized human cancer cells to apoptosis induced by DNA-damaging agents or oxidative stress. We encapsulated thiostrepton into micelle-nanoparticles and after injection we detected accumulation of nanoparticles in tumors and in the livers of treated mice. This treatment led to inhibition of human xenograft tumor growth in nude mice. Our data indicate that targeting FOXM1 increases apoptosis and inhibits tumor growth.
authors.affiliation: Department of Medicine, University of Illinois at Chicago, Chicago, IL 606012, USA.
authors.forename: Andrei L
authors.initials: AL
authors.lastname: Gartel
references.citation: Biochim Biophys Acta. 2007 Jan;1775(1):92-102
references.pmid: 17014965
references.citation: Cancer Res. 2007 Sep 1;67(17):8293-300
references.pmid: 17804744
references.citation: Cancer Biol Ther. 2012 Feb 1;13(3):184-9
references.pmid: 22353937
references.citation: Chem Biol. 2009 Dec 24;16(12):1278-89
references.pmid: 20064438
references.citation: Am J Pathol. 2013 Jul;183(1):257-65
references.pmid: 23665201
references.citation: Oncogene. 2009 Dec 3;28(48):4295-305
references.pmid: 19749794
references.citation: Biochem J. 2013 Sep 1;454(2):201-8
references.pmid: 23772801
references.citation: Front Oncol. 2013 Jun 06;3:150
references.pmid: 23761863
references.citation: Neoplasia. 2004 Nov-Dec;6(6):744-50
references.pmid: 15720800
references.citation: Cell Cycle. 2009 Oct 15;8(20):3425-7
references.pmid: 19806025
references.citation: Haematologica. 2012 Jul;97(7):1092-100
references.pmid: 22271891
references.citation: Oncotarget. 2011 Dec;2(12):1218-26
references.pmid: 22203467
references.citation: Cell Cycle. 2010 Mar 15;9(6):1214-7
references.pmid: 20410687
references.citation: J Clin Invest. 2007 Jan;117(1):99-111
references.pmid: 17173139
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Nat Rev Cancer. 2008 Mar;8(3):c1; author reply c2
references.pmid: 18297053
references.citation: Cell Cycle. 2011 Dec 15;10(24):4341-2
references.pmid: 22134246
references.citation: J Pathol. 2008 Jul;215(3):245-52
references.pmid: 18464245
references.citation: Prostate. 2010 Jun 1;70(8):825-33
references.pmid: 20058240
references.citation: Cell Cycle. 2011 Oct 1;10(19):3269-73
references.pmid: 21941087
references.citation: Cancer Res. 2011 Jul 1;71(13):4329-33
references.pmid: 21712406
references.citation: Cell Cycle. 2008 Jun 15;7(12):1851-5
references.pmid: 18583930
references.citation: PLoS One. 2009;4(5):e5592
references.pmid: 19440351
references.citation: Mol Cancer Ther. 2013 Mar;12(3):245-54
references.pmid: 23443798
references.citation: Biochem Pharmacol. 2013 Mar 1;85(5):644-652
references.pmid: 23103567
references.citation: Cancer Res. 2006 Oct 1;66(19):9731-5
references.pmid: 17018632
references.citation: PLoS One. 2011 Feb 18;6(2):e17110
references.pmid: 21365012
references.citation: Cancer Biol Ther. 2011 Jan 1;11(1):43-7
references.pmid: 21119308
references.citation: PLoS One. 2012;7(2):e31761
references.pmid: 22393369
references.citation: Mol Cancer Ther. 2011 Dec;10(12):2287-97
references.pmid: 21903609
references.citation: Genes Dev. 2004 Apr 1;18(7):830-50
references.pmid: 15082532
references.citation: Cell Cycle. 2009 Jun 15;8(12):1966-7
references.pmid: 19411834
references.citation: PLoS One. 2009 Aug 12;4(8):e6593
references.pmid: 19672316
references.citation: J Biol Chem. 2011 Dec 2;286(48):41425-41433
references.pmid: 21979956